| Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials. | |
| | |
MedLine Citation:
|
PMID: 20452475 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Effects of soy isoflavone supplements on bone turnover markers remain unclear. This up-to-date systematic review and meta-analysis of randomized controlled trials (RCTs) was performed primarily to more completely and precisely clarify the effects on urinary deoxypyridinoline (DPD) and serum bone alkaline phosphatase (BAP) and secondarily to evaluate the effects on other bone turnover markers, compared with placebo in menopausal women. METHODS: PubMed, CENTRAL, ICHUSHI, and CNKI were searched in June 2009 for relevant studies of RCTs. Data on study design, participants, interventions, and outcomes were extracted and methodological quality of each included trial was assessed. RESULTS: From 3740 identified relevant articles, 10 (887 participants), 10 (1210 participants), and 8 (380 participants) RCTs were selected for meta-analysis of effects on DPD, BAP, and serum osteocalcin (OC), respectively, using Review Manager 5.0.22. Daily ingestion of an average 56 mg soy isoflavones (aglycone equivalents) for 10 weeks to 12 months significantly decreased DPD by 14.1% (95% CI: -26.8% to -1.5%; P=0.03) compared to baseline (heterogeneity: P<0.00001; I(2)=93%; random effects model). The overall effect of soy isoflavones on DPD compared with placebo was a significant decrease of -18.0% (95% CI: -28.4% to -7.7%, P=0.0007; heterogeneity: P=0.0001; I(2)=73%; random effects model). Subgroup analyses and meta-regressions revealed that isoflavone dose and intervention duration did not significantly relate to the variable effects on DPD. Daily supplementation of about 84 mg and 73 mg of soy isoflavones for up to 12 months insignificantly increased BAP by 8.0% (95% CI: -4.2% to 20.2%, P=0.20; heterogeneity: P<0.00001; I(2)=98%) and OC by 10.3% (95% CI: -3.1% to 23.7%, P=0.13; heterogeneity: P=0.002; I(2)=69%) compared with placebo (random effects model), respectively. CONCLUSIONS: Soy isoflavone supplements moderately decreased the bone resorption marker DPD, but did not affect bone formation markers BAP and OC in menopausal women. The effects varied between studies, and further studies are needed to address factors relating to the observed effects of soy isoflavones on DPD and to verify effects on other bone turnover markers. |
| | |
Authors:
|
Kyoko Taku; Melissa K Melby; Mindy S Kurzer; Shoichi Mizuno; Shaw Watanabe; Yoshiko Ishimi |
Related Documents
:
|
17390085 - Association of candidate gene polymorphisms with bone mineral density in community-dwel... 8654625 - Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog... 19034375 - High bone mineral density is associated with high body mass index. 7820775 - Relations between calcidiol serum levels and bone mineral density in postmenopausal wom... 16332225 - Assessing risks of releasing exotic biological control agents of arthropod pests. 20622025 - Residual attraction to smoking and smoker identity following smoking cessation. |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review Date: 2010-05-07 |
Journal Detail:
|
Title: Bone Volume: 47 ISSN: 1873-2763 ISO Abbreviation: Bone Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-12 Completed Date: 2010-10-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8504048 Medline TA: Bone Country: United States |
Other Details:
|
Languages: eng Pagination: 413-23 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Information Center, National Institute of Health and Nutrition, Shinjuku-ku, Tokyo, Japan. takuk@nih.go.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Alkaline Phosphatase / blood Amino Acids / urine Biological Markers / blood Bone Remodeling / drug effects* Collagen Type I / blood Dietary Supplements* Female Humans Isoflavones / pharmacology* Menopause / blood*, drug effects*, urine Middle Aged Osteocalcin / blood Peptide Fragments / blood Peptides / blood Procollagen / blood Randomized Controlled Trials as Topic* Soybeans / chemistry* |
| Chemical | |
Reg. No./Substance:
|
0/Amino Acids; 0/Biological Markers; 0/Collagen Type I; 0/Isoflavones; 0/Peptide Fragments; 0/Peptides; 0/Procollagen; 0/collagen type I trimeric cross-linked peptide; 0/procollagen Type I N-terminal peptide; 104982-03-8/Osteocalcin; 90032-33-0/deoxypyridinoline; EC 3.1.3.1/Alkaline Phosphatase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Age but not Gender Modulates the Relationship between PTH and Vitamin D.
Next Document: Use of Tuohy needle for intraamniotic methotrexate injection through the cervical canal in a cervica...